Shopping Cart
Remove All
Your shopping cart is currently empty
BC-1215 is an inhibitor of F-box protein 3 (FBXO3, a ubiquitin E3 ligase component, IC50=0.9 μg/mL for IL-1β release).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $47 | In Stock | In Stock | |
| 10 mg | $77 | In Stock | In Stock | |
| 25 mg | $128 | In Stock | In Stock | |
| 50 mg | $189 | In Stock | In Stock | |
| 100 mg | $279 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $52 | In Stock | In Stock |
| Description | BC-1215 is an inhibitor of F-box protein 3 (FBXO3, a ubiquitin E3 ligase component, IC50=0.9 μg/mL for IL-1β release). |
| Targets&IC50 | FBXO3:0.9 μg/mL |
| In vivo | A small molecule inhibitor BC-1215 argeting Fbxo3 was sufficient to lessen severity of cytokine-driven inflammation in several murine disease models. |
| Animal Research | Tested effects of administration of BC-1215 in a model of a cecal ligation and puncture (CLP)-induced sepsis. Mice with CLP had significantly increased cytokine release compared to sham treated mice. BC-1215 treatment significantly attenuated CLP-induced secretion of all three circulating pro-inflammatory cytokines in mice . BC-1215 also decreased bacterial counts in the CLP model and modestly produced inhibition of bacterial growth using Kirby Bauer testing |
| Molecular Weight | 394.51 |
| Formula | C26H26N4 |
| Cas No. | 1507370-20-8 |
| Smiles | C(CNCc1ccc(cc1)-c1ccccn1)NCc1ccc(cc1)-c1ccccn1 |
| Relative Density. | 1.125 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 3.95 mg/mL (10.01 mM), Sonication is recommended. | ||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.53 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.